Business Activities

Under its Purpose, “Tomorrow and Beyond, Healthy for All Life,” ASKA Pharmaceutical Holdings Group creates value by leveraging the expertise in the hormone field and strengths in specialty areas that it has cultivated over more than 100 years. Building on its core competencies, namely highly skilled people and organizational capabilities, trusted relationships with stakeholders, and a strong presence in specialty fields, the Group is advancing five growth-driving businesses: Domestic Prescription Pharmaceuticals, Drug Discovery, Global Business, Animal Health, and Diagnostics & Around-the-Pill Solutions.
Drawing on the expertise and customer base developed through its Domestic Prescription Pharmaceuticals business, the Group is expanding its business portfolio through the creation of new value in drug discovery, global expansion centered on Asia, applications in the animal health field, and total healthcare solutions encompassing diagnostics, testing, and prognostic care. Through synergies among these businesses, the Group seeks to address social challenges and achieve sustainable growth, with the goal of becoming a globally recognized specialty healthcare company creating value worldwide by 2035.

The business has established a strong presence in specialty fields, particularly obstetrics and gynecology and thyroid disorders, providing a solid earnings foundation for the Group. Through the launch of new products, expansion into new therapeutic areas, and the utilization of digital therapeutics, the business aims to deliver greater medical value while creating new growth opportunities.

Principal Group Company

With a strategic focus on women’s health, the Group is strengthening its drug discovery capabilities and enhancing competitiveness through ion channel-based drug discovery and the incorporation of innovative modalities via open innovation. By advancing the development and out-licensing of proprietary drug candidates, the Group seeks to generate sustainable medium- to long-term growth and revenue opportunities.

Principal Group Company

The Group is advancing its business expansion in Southeast Asia, particularly in Vietnam and the Philippines, while reinforcing its supply chain through the utilization of Hataphar’s new manufacturing facility. By developing products that address local healthcare needs, the Group is strengthening its presence in overseas markets and accelerating sustainable revenue growth.

Principal Operating Companies

Focusing on the reproductive and endocrine fields, the Group provides products for both livestock and companion animals. By introducing new products and expanding its presence in international markets, the Group aims to further grow its Animal Health business, strengthen its revenue base, and contribute to the realization of a harmonious society where people and animals coexist.

Principal Group Company

Building on its expertise in hormone measurement technologies, the Group develops its diagnostics business and promotes the wider adoption of non-invasive testing solutions. Furthermore, through expansion into the around-the-pill domain and collaboration with external partners, the Group is creating new sources of revenue in healthcare-related areas surrounding pharmaceutical products and services.

Principal Operating Companies